Glenmark Pharmaceuticals stock (INE935A01035): Drops 2.48% in fifth straight session

Glenmark Pharmaceuticals Ltd shares declined 2.48% to Rs 2289.1 on the NSE as of 13:19 IST on May 12, 2026, extending losses for a fifth straight session, Business Standard as of 05/12/2026. Despite the daily drop, the stock has surged 61.5% over the past year, outperforming the Nifty index's 4.21% decline and the Nifty Pharma index's 12.6% gain.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Glenmark Pharmaceuticals: core business model

Glenmark Pharmaceuticals Ltd develops, manufactures and markets branded and generic formulations globally. The company operates in therapeutic areas including dermatology, respiratory, and cardiovascular diseases. Headquartered in Mumbai, India, it has a presence in over 80 countries with key manufacturing facilities in India, the US and Europe, according to its official website.

For US investors, Glenmark's exposure comes via its US generics business, which supplies affordable drugs to the American market amid ongoing demand for cost-effective pharmaceuticals.

Main revenue and product drivers for Glenmark Pharmaceuticals

Net sales for the six months ending December 2025 reached ?9,947.49 crores, up 45.83% year-over-year, with profit after tax at ?2,026.77 crores, as reported as of May 12, 2026 by MarketsMojo as of 05/12/2026. Key drivers include generics in the US and Europe, alongside specialty branded drugs in emerging markets.

Institutional holdings stand at 39.67%, signaling confidence from major investors, per the same source dated May 12, 2026.

Industry trends and competitive position

The Indian pharma sector benefits from US FDA approvals and generic competition in high-value drugs. Glenmark holds a midcap position with strengths in complex generics and R&D in novel therapies, relevant for US investors tracking global supply chains for affordable meds.

Conclusion

Glenmark Pharmaceuticals shows robust one-year gains and strong recent financials despite a short-term price dip on May 12, 2026. With solid sales growth and institutional interest, it remains a notable player in global pharma. US investors may note its generics footprint in the American market.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.